An analysis of a deal between the Trump administration and Eli Lilly and Novo Nordisk regarding the pricing of GLP-1 agonists. The agreement aimed to lower drug costs to $245 monthly for Medicare and Medicaid in exchange for increased volume, but private insurers' reluctance to cover obesity treatments has complicated the implementation. The article suggests that while the policy intended to expand access, the pharmaceutical giants are likely to benefit from the increased volume without significantly sacrificing price.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.